Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bupropion-SR Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Framing Messages for Smoking Cessation With Bupropion - 6

NCT00104598
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Smoking Abstinence Program
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional

Bupropion as an Adjunct to the Nicotine Patch Plus CBT

NCT00142831
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Pharmacotherapies for Smoking Cessation
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
20 Years to 65 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

NCT00218231
View directory record Official record
Conditions
Schizophrenia, Tobacco Use Disorder
Interventions
300 mg/day bupropion-sr, 0 mg/day bupropion-sr
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery

NCT02173886
View directory record Official record
Conditions
Roux en Y Gastric Bypass
Interventions
Bupropion SR and XL
Drug
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 17, 2026, 2:30 PM EDT
Not listed Phase 2 Interventional

Lamotrigine and Bupropion for Meniere's Disease

NCT05420350
View directory record Official record
Conditions
Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions
Lamotrigine and Bupropion, Placebo
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 2:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Symptom Burden in Head and Neck Cancer

NCT01219673
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Placebo, Armodafinil, Minocycline, Bupropion
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy

NCT01286402
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion SR, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

NCT00567255
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

NCT03045341
View directory record Official record
Conditions
Binge-eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Maintenance Treatment for Smoking Cessation

NCT01615770
View directory record Official record
Conditions
Smoking
Interventions
cognitive behavior therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

NCT00474630
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
53
States / cities
Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

NCT00865111
View directory record Official record
Conditions
Healthy
Interventions
Bupropion 150 mg Extended-Released Tablet, single dose, Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

NCT01764386
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB, CLI, Usual Care
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Denver, Colorado • St Louis, Missouri • Cary, North Carolina + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

NCT00307203
View directory record Official record
Conditions
Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions
bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 2:30 PM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

NCT02162862
View directory record Official record
Conditions
Sleep Disturbance, Fatigue, Inflammatory Bowel Disease
Interventions
Behavioral Counseling, bupropion-SR
Behavioral · Drug
Lead sponsor
Eva Szigethy
Other
Eligibility
15 Years to 30 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional

Combination Medications vs. Patch Alone for Medically-Ill Smokers

NCT00770666
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine patch, nicotine inhaler, bupropion, Nicotine patch
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2008 · Synced Oct 17, 2026, 2:30 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

NCT00511134
View directory record Official record
Conditions
Insomnia, Nicotine Dependence
Interventions
Eszopiclone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

NCT00339014
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide CR and Bupropion SR, Placebo
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 17, 2026, 2:30 PM EDT
Terminated Phase 4 Interventional

Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder

NCT00181896
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
bupropion SR
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2011 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

NCT00129272
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder
Interventions
Bupropion-SR, Placebo
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
12 Years to 25 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Bupropion SR for Treating Smokeless Tobacco Use

NCT00414180
View directory record Official record
Conditions
Smokeless Tobacco
Interventions
Bupropion SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 17, 2026, 2:30 PM EDT